The company has demonstrated a strong financial turnaround, becoming profitable with net income reaching AED 166.7 million for the first nine months of 2025. Short-term assets comfortably cover both short and long-term liabilities while debt levels are well-managed with a satisfactory net debt to equity ratio of 1%. The company's P/E ratio of 21.9x is below the industry average, indicating potential value for investors.
Cyborg Score Rationale
Strong financial turnaround with net income of AED 166.7 million in 9M 2025. Well-managed debt and high earnings quality offset concerns of low ROE at 6.5% and high share price volatility.
Top Insights
Returned to profitability in 2025 with AED 166.7 million net income for 9M period
Strong liquidity position with short-term assets exceeding all liabilities and minimal debt-to-equity ratio
Recent strategic licensing partnership with Dong A ST for biotechnology product launch in MENA region
Stock showed strong momentum with 72.5% YTD gain as of latest data
Named Competitors
Generic Pharmaceuticals — Competing regional pharma manufacturers in GCC markets
Recent Developments
(March 2025) Strategic Licensing Partnership with Dong A ST for innovative biotechnology product in MENA
(February 2025) Completed divestment of Zahrat Al Rawdah Pharmacies subsidiary
(November 2025) Delivered consistent sales growth and stable profit in YTD September results
(August 2025) Strong Q2 H1 performance with revenue growth and margin expansion
Open the full interactive Gulf Pharmaceutical Industries P.S.C. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.